Applied DNA, CEA Supercharge BNB Holdings in Bold Treasury Overhaul

Applied DNA Sciences (NASDAQ: BNBX), a pioneering biotech firm blending blockchain and biopharma, announced a significant leap in its digital asset treasury strategy with a $27 million private placement and a boosted BNB holding valued over $17 million.

This move advances their focus on a yield-driven BNB treasury approach, combining institutional-grade blockchain assets with streamlined corporate finances.

The private investment in public equity (PIPE) financing, driven by top DeFi and TradFi institutional investors, infused Applied DNA with $15.3 million in cash and stablecoins, alongside nearly $12 million in units of the OBNB trust.

Additionally, the company acquired 4,908 more BNB tokens valued at $5.3 million as of October 20, 2025.

These strategic purchases underscore Applied DNA's commitment to positioning BNB as a cornerstone asset in their treasury portfolio.

Strategic Shift Into Institutional-Grade Blockchain

Applied DNA’s Chief Investment Officer, Patrick Horsman, highlighted the company’s excitement about launching a yield-focused BNB treasury strategy with direct and equivalent token exposures.

Horsman described BNB as "the next institutional-grade blockchain," aiming to harness its growth potential while extracting yield from these high-quality crypto assets.

The collaboration between traditional finance and decentralized finance investors in the PIPE symbolizes growing mainstream trust in crypto-driven treasury models.

CEO Clay Shorrock emphasized operational discipline and long-term sustainability through cost structure optimization.

He noted, “By aligning resources with strategic priorities, we have positioned the company well to deliver durable shareholder value." The company reported annualized cost savings of approximately $2.9 million, reinforcing its strategic pivot toward efficient, blended treasury management.

BNB at the Core of Treasury Innovation

Applied DNA’s treasury blueprint integrates cash management with blockchain-native yield opportunities—offering investors exposure to a digital asset traditionally out of reach for many.

The prefunded warrants and OBNB trust units representing BNB tokens are pending stockholder approval but, once cleared, the company will hold over 10,000 BNB tokens directly through these trust units.

This dual investment in cash and crypto assets reflects a broader trend in corporate finance, where Nasdaq-listed firms diversify into digital assets to enhance liquidity and future-proof capital strategies.

The new funds will fuel ongoing implementation of this strategy alongside working capital and transactional expenses.

Applied DNA’s push aligns with rising institutional interest in blockchain treasury diversification.

The company’s initiative represents one of the biotech sector’s boldest moves into decentralized finance.